Tradestie Institutional Equity Comparison Engine
GRML vs MDCX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MDCX Overall Edge
MDCX Captures Institutional Edge (1โ1 Pillars ยท 7โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Medicus Pharma Ltd. Common Stock (MDCX) driven by superior Growth & Margin while GRML counters with relative strength in Momentum & Technical. Fundamentally, GRML trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus MDCX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, GRML sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against MDCX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
GRML N/M vs MDCX N/M Fwd P/E
Growth & Margin Winner
MDCX
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner
GRML
1Y +650.0% vs -25.7% ยท 52W Pos 19% vs 35%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
GRML
US Equity
GRML
Institutional Equity
$3.51
-2.77% 1D
Market Cap
N/A
1M Return
-41.5%
1Y Return
+650.0%
Forward P/E
N/M
Unified AI Score
56.8 / 100
HOLD
Tech 60.0
Fund 57.0
Flow 50.0
Mom 60.0
MDCX
NASDAQ
Medicus Pharma Ltd. Common Stock
Pharmaceutical Preparations
$1.68
-13.85% 1D
Market Cap
$3.6M
1M Return
-48.31%
1Y Return
-25.66%
Forward P/E
N/M
Unified AI Score
61.9 / 100
BUY
Tech 83.0
Fund 60.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
GRML +650.0%
MDCX -25.66%
Spread: +414.0 pp (GRML Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
GRML TTM Op. Margin: N/A
MDCX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GRML vs MDCX. Trailing 12-month operating profitability (GRML N/A vs MDCX 0.0%) and valuation multiples (GRML N/M vs MDCX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | GRML | MDCX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $3.6M | Larger Scale | MDCX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | +0.0% | Higher Growth | MDCX |
| Operating Margin (TTM) Profitability | N/A | 0.0% | Higher Margin | MDCX |
| Net Profit Margin Profitability | N/A | 0.0% | Higher Margin | MDCX |
| Return on Equity (ROE) Capital Efficiency | N/A | -7446.1% | Higher ROE | MDCX |
| 52-Week Range Position Momentum | 19% ($0โ$18) | 35% ($0โ$5) | Stronger Trend | MDCX |
| Beta / 30D Volatility Risk Regime | -5.32ฮฒ ยท 95% Vol | -1.42ฮฒ ยท 108% Vol | Lower Realized Risk | GRML |
| Unified Institutional Score Composite Signal | 56.8 / 100 (HOLD) | 61.9 / 100 (BUY) | Higher Composite | MDCX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full GRML vs MDCX Buy Guide
GRML
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
MDCX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither GRML nor MDCX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.